1.09
+0.1295(+13.48%)
Currency In USD
| Previous Close | 0.96 |
| Open | 0.99 |
| Day High | 1.19 |
| Day Low | 0.98 |
| 52-Week High | 2.81 |
| 52-Week Low | 0.4 |
| Volume | 5.6M |
| Average Volume | 2.06M |
| Market Cap | 87.88M |
| PE | 2.87 |
| EPS | 0.38 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 0.97 |
| Change | 0.13 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $84.5 as of May 09, 2025 at a share price of $1.09. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $75.38 as of May 09, 2025 at a share price of $1.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monda
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:00 PM GMT
Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerabilitySOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, I
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
GlobeNewswire Inc.
Mar 05, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and c